An information-theoretic approach to surrogate-marker evaluation with failure time endpoints

被引:0
作者
Assam Pryseley
Abel Tilahun
Ariel Alonso
Geert Molenberghs
机构
[1] Duke-NUS Graduate Medical School,Singapore Clinical Research Institute Pte Ltd
[2] Center for Biostatistics in AIDS Research,Harvard School of Public Health, Department of Biostatistics
[3] Maastricht University,Department of Methodology and Statistics
[4] Katholieke Universiteit Leuven,I
[5] Universiteit Hasselt,BioStat
来源
Lifetime Data Analysis | 2011年 / 17卷
关键词
Cancer; Censoring; Information theory; Likelihood reduction factor; Surrogate Marker;
D O I
暂无
中图分类号
学科分类号
摘要
Over the last decades, the evaluation of potential surrogate endpoints in clinical trials has steadily been growing in importance, not only thanks to the availability of ever more potential markers and surrogate endpoints, also because more methodological development has become available. While early work has been devoted, to a large extent, to Gaussian, binary, and longitudinal endpoints, the case of time-to-event endpoints is in need of careful scrutiny as well, owing to the strong presence of such endpoints in oncology and beyond. While work had been done in the past, it was often cumbersome to use such tools in practice, because of the need for fitting copula or frailty models that were further embedded in a hierarchical or two-stage modeling approach. In this paper, we present a methodologically elegant and easy-to-use approach based on information theory. We resolve essential issues, including the quantification of “surrogacy” based on such an approach. Our results are put to the test in a simulation study and are applied to data from clinical trials in oncology. The methodology has been implemented in R.
引用
收藏
页码:195 / 214
页数:19
相关论文
共 118 条
[1]  
Alonso A(2007)Surrogate marker evaluation from an information theory perspective Biometrics 63 180-186
[2]  
Molenberghs G(2008)Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective Stat Methods Med Res 17 497-504
[3]  
Alonso A(2004)Prentice’s approach and the meta-analytic paradigm: a reflection on the role of statistics in the evaluation of surrogate endpoints Biometrics 60 724-728
[4]  
Molenberghs G(2005)A unifying approach for surrogate marker validation based on Prentice’s criteria Stat Med 25 205-211
[5]  
Alonso A(2006)A unifying approach for surrogate marker validation based on Prentices criteria Stat Med 25 205-221
[6]  
Molenberghs G(1877)Über die Beziehung zwischen dem zweiten Hauptsatze der mechanischen Wärmetheorie und der Wahrscheinlichkeitsrechnung respecktive den Sätzen über das Wärmegleichgewicht (On the relationship between the second law of the mechanical theory of heat and the probability calculus) Wiener Berichte 2 373-435
[7]  
Burzykowski T(2001)Validation of surrogate endpoints in multiple randomized clinical trials with failure-time endpoints Appl Stat 50 405-422
[8]  
Renard D(2000)The validation of surrogate endpoints in meta-analyses of randomized experiments Biostatistics 1 49-67
[9]  
Geys H(1989)Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infraction N Engl J Med 321 406-412
[10]  
Shkedy Z(1978)A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence Biometrika 65 41-151